Healthcare Sales & Marketing Network News: empagliflozin

Searching News Database: empagliflozin

HSMN NewsFeed - 30 Jul 2020
Jardiance(R) meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in phase III trial in adults with and without diabetes
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 26 Jun 2019
U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure
Biopharmaceuticals Cardiology FDA

HSMN NewsFeed - 14 Feb 2019
Boehringer Ingelheim and Lilly announce the CAROLINA(R) cardiovascular outcome trial of Tradjenta(R) met its primary endpoint of non-inferiority compared with glimepiride
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 4 Oct 2018
Boehringer Ingelheim and Lilly present full results from EASE Phase III program for empagliflozin as adjunct to insulin in type 1 diabetes
Biopharmaceuticals Endocrinology

HSMN NewsFeed - 29 Jun 2016
FDA Advisory Committee recommends approval of Jardiance(R) (empagliflozin) for cardiovascular indication in 12-11 vote
Biopharmaceuticals Endocrinology Cardiology FDA

HSMN NewsFeed - 20 Aug 2015
Jardiance(R) Demonstrated Cardiovascular (CV) Risk Reduction in People with Type 2 Diabetes at High Risk for CV Events
Biopharmaceuticals Endocrinology

Return to NewsFeed

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.